Chemomab Therapeutics Ltd. (CMMB) NASDAQ

$0.78 0.01 (1.17%)

Market Cap: $1.43M

As of 03/28/24 04:00 PM EDT. Market closed.

(CMMB)

Chemomab Therapeutics Ltd. (CMMB)
NASDAQ

$0.78
0.01 (1.17%)

Market Cap: $1.43M

As of 03/28/24 04:00 PM EDT. Market closed.

Add to Portfolio

chemomab ltd. is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need. chemomab is making great strides with its novel cm-101 proprietary platform, which hinders the fundamental function of the soluble chemokine ccl24 as a regulator of major inflammatory and fibrotic pathways in multiple ... read more

chemomab ltd. is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need. chemomab is making great strides with its novel cm-101 proprietary platform, which hinders the fundamental function of the soluble chemokine ccl24 as a regulator of major inflammatory and fibrotic pathways in multiple fibrosis-related disorders. cm-101, the company’s lead clinical candidate, is a first-in-class monoclonal antibody that targets ccl24. chemomab has shown that cm-101 interferes with the underlying biology of fibrosis using a novel and differentiated mechanism of action. chemomab is actively advancing cm-101 into phase 2 studies to treat patients with liver fibrosis (primary sclerosing cholangitis and non-alcoholic steatohepatitis) and patients suffering from skin and lung fibrosis (systemic sclerosis). read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
URL
Address
.
Sector
Manufacturing
Industry
Pharmaceutical Preparation Manufacturing
Address
.
PRICE CHART FOR CHEMOMAB THERAPEUTICS LTD
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$0.77
Previous Close
$0.77
Days Range
$0.70 - $0.78
52 week range
$0.42 - $1.89
Volume
28,961
Avg. Volume (30 days)
96,938
Market Cap
$1.43M
Dividend Yield
-
P/E
-
Shares Outstanding
1,839,633
Open
$0.77
Previous Close
$0.77
Days Range
$0.70 - $0.78
52 week range
$0.42 - $1.89
Volume
28,961
Avg. Volume (30 days)
96,938
Market Cap
$1.43M
Dividend Yield
-
P/E
-
Shares Outstanding
1,839,633
FINANCIAL STATEMENTS FOR CHEMOMAB THERAPEUTICS LTD
LOADING...

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR CHEMOMAB THERAPEUTICS LTD
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
OrbiMed Israel GP Ltd.10% OwnerJan 03, 2023 Sale$3.58336,9001,207,7592,311,798Jan 05, 2023, 04:49 PM
Mor George AdiChief Scientific OfficerJan 03, 2023 Sale$5.036,10030,663251,147Jan 05, 2023, 04:01 PM
Mor George AdiChief Scientific OfficerJan 03, 2023 Sale$5.037,70038,706317,075Jan 05, 2023, 04:01 PM
Cohen Neil HarrisDirectorNov 16, 2022 Sale$2.002,4094,81810,000Nov 18, 2022, 07:53 AM
Mor George AdiChief Scientific OfficerNov 16, 2022 Sale$2.08257,248536,311257,247Nov 17, 2022, 04:56 PM
Mor George AdiChief Scientific OfficerNov 16, 2022 Sale$2.08324,775677,091324,775Nov 17, 2022, 04:56 PM
Marvin DonaldExecutive VP, CFO & COOMar 16, 2022 Buy$3.275001,6372,000Jun 21, 2022, 06:01 AM
Maryles Joel MichaelDirectorMay 24, 2022 Buy$2.884331,2471,433May 25, 2022, 04:03 PM
Cohen Neil HarrisDirectorMay 18, 2022 Buy$3.192,0006,38012,409May 19, 2022, 04:02 PM
Maryles Joel MichaelDirectorMar 18, 2022 Buy$4.341,0004,3401,000Mar 21, 2022, 06:04 AM
Marvin DonaldExecutive VP, CFO & COOMar 14, 2022 Buy$4.041,2505,0451,500Mar 21, 2022, 06:02 AM
Pfost Dale RChief Executive OfficerMar 14, 2022 Buy$3.982,5009,9432,500Mar 15, 2022, 04:10 PM
Cohen Neil HarrisDirectorMar 14, 2022 Buy$4.356,00026,12010,409Mar 15, 2022, 04:07 PM
Darvish NissimDirectorMar 11, 2022 Buy$4.281,2005,1361,200Mar 14, 2022, 04:20 PM
Cohen Neil HarrisDirectorDec 06, 2021 Buy$7.432,00014,8604,409Dec 08, 2021, 07:29 AM
Cohen Neil HarrisDirectorMar 16, 2021 Buy$41.512,40999,9982,409Mar 26, 2021, 10:27 AM
OrbiMed Israel GP Ltd.10% OwnerMar 16, 2021 Option Exercise$17.35288,1704,999,7502,578,174Mar 18, 2021, 09:59 PM
Load More Insider Transactions
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
OrbiMed Israel GP Ltd.10% Owner01/03/20231,207,759
Mor George AdiChief Scientific Officer01/03/202330,663
Mor George AdiChief Scientific Officer01/03/202338,706
Cohen Neil HarrisDirector11/16/20224,818
Mor George AdiChief Scientific Officer11/16/2022536,311
Mor George AdiChief Scientific Officer11/16/2022677,091
Marvin DonaldExecutive VP, CFO & COO03/16/20221,637
Maryles Joel MichaelDirector05/24/20221,247
Cohen Neil HarrisDirector05/18/20226,380
Maryles Joel MichaelDirector03/18/20224,340
Marvin DonaldExecutive VP, CFO & COO03/14/20225,045
Pfost Dale RChief Executive Officer03/14/20229,943
Cohen Neil HarrisDirector03/14/202226,120
Darvish NissimDirector03/11/20225,136
Cohen Neil HarrisDirector12/06/202114,860
Cohen Neil HarrisDirector03/16/202199,998
OrbiMed Israel GP Ltd.10% Owner03/16/20214,999,750
Load More Insider Transactions
FUNDS WITH A POSITION IN CHEMOMAB THERAPEUTICS LTD
Fund# Shares Owned% of Portfolio% ChangeInvesting Style
ORBIMED ADVISORS LLC2,241,2740.02%No changeOther
GEODE CAPITAL MANAGEMENT, LLC11,7370%No changeOther
CHANGE IN SHARES OUTSTANDING FOR CHEMOMAB THERAPEUTICS LTD
STOCK BUYBACKS FOR CHEMOMAB THERAPEUTICS LTD
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
12/31/2023
09/30/2023
10.08%
1Q
12/31/2023
06/30/2023
17.41%
2Q
12/31/2023
03/31/2023
17.77%
3Q
12/31/2023
12/31/2022
15.52%
4Q
12/31/2023
09/30/2022
13.77%
5Q
12/31/2023
06/30/2022
14.07%
6Q
12/31/2023
03/31/2022
14.11%
7Q
12/31/2023
12/31/2021
6.67%
8Q
12/31/2023
09/30/2021
14.18%
9Q
12/31/2023
06/30/2021
20.35%
10Q
12/31/2023
03/31/2021
66.04%
11Q
12/31/2023
12/31/2020
80.82%
12Q
12/31/2023
09/30/2020
86.71%
13Q
Load More

Period of Report: 12/31/2023

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
09/30/2023
10.08%
1Q
06/30/2023
17.41%
2Q
03/31/2023
17.77%
3Q
12/31/2022
15.52%
4Q
09/30/2022
13.77%
5Q
06/30/2022
14.07%
6Q
03/31/2022
14.11%
7Q
12/31/2021
6.67%
8Q
09/30/2021
14.18%
9Q
06/30/2021
20.35%
10Q
03/31/2021
66.04%
11Q
12/31/2020
80.82%
12Q
09/30/2020
86.71%
13Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR CHEMOMAB THERAPEUTICS LTD
LOADING...